GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » 3-Year FCF Growth Rate

Ensol Biosciences (XKRX:140610) 3-Year FCF Growth Rate : -7.00% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences 3-Year FCF Growth Rate?

Ensol Biosciences's Free Cash Flow per Share for the six months ended in Dec. 2023 was ₩-765.27.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -7.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -15.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 10 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Ensol Biosciences was 15.10% per year. The lowest was -29.00% per year. And the median was -2.70% per year.


Competitive Comparison of Ensol Biosciences's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Ensol Biosciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ensol Biosciences's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensol Biosciences's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Ensol Biosciences's 3-Year FCF Growth Rate falls into.



Ensol Biosciences 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Ensol Biosciences  (XKRX:140610) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Ensol Biosciences 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Ensol Biosciences (XKRX:140610) Business Description

Traded in Other Exchanges
N/A
Address
51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences (XKRX:140610) Headlines

No Headlines